Predictive Value of Circulating Tumor Cells Based on Subtraction Enrichment for Recurrence Risk in Stage II Colorectal Cancer

Current guidelines recommend adjuvant chemotherapy (ACT) for stage II colorectal cancer (CRC) patients by using clinical high risk factors, with which circulating tumor cells (CTCs) were not considered. Here, an assessment to detect CTCs based on subtraction enrichment mediated by magnetic beads conjugated with CD45, immunofluorescence staining of CK, and fluorescence in situ hybridization of CEP8 is established. Both CEP8-and CK-positive CTCs have the potential to improve the risk stratification of stage II CRC patients. Patients with preoperative CTCs of >= 4 had a significantly higher recurrence risk than those with preoperative CTCs of < 4 in two external validation cohorts (P < 0.0001). In the subgroup with clinical high risk, when preoperative CTCs were < 4, patients did not benefit from ACT (P = 0.5764); however, when preoperative CTCs were >= 4, patients received benefit from ACT (P = 0.0064). Additionally, regardless of clinical risk status and preoperative CTC levels, if postoperative CTC levels were >= 4 for more than three consecutive time points (monitoring time interval, 2-6 months), the recurrence rate was 100%. Our findings suggested that the subtraction enrichment of CTCs could provide a reliable method to stratify the recurrence risk and make therapeutic decisions after surgery in stage II CRC patients.

Automated summary

Based on the assessment of CTCs, this study found that CEP8 and CK-positive CTCs have the potential to improve the risk stratification of stage II CRC patients. In the subgroup with clinical high risk, the number of preoperative CTCs is associated with treatment outcome. Moreover, if postoperative CTC levels remain above 4 for more than three consecutive time points, the recurrence rate is 100%.